BIOLASE Inc (NASDAQ:BIOL) – Stock analysts at Dougherty & Co issued their FY2021 EPS estimates for shares of BIOLASE in a research note issued to investors on Wednesday, January 1st, according to Zacks Investment Research. Dougherty & Co analyst K. Bauser anticipates that the medical technology company will earn ($0.22) per share for the year.
A number of other brokerages have also commented on BIOL. ValuEngine upgraded shares of BIOLASE from a “hold” rating to a “buy” rating in a research note on Thursday, October 17th. Zacks Investment Research raised shares of BIOLASE from a “sell” rating to a “hold” rating in a research note on Tuesday, January 7th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $2.17.
Shares of NASDAQ BIOL traded down $0.06 during midday trading on Monday, hitting $0.66. 2,202 shares of the stock traded hands, compared to its average volume of 209,279. The business has a 50 day moving average price of $0.61 and a two-hundred day moving average price of $0.90. BIOLASE has a one year low of $0.43 and a one year high of $2.87. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.84 and a current ratio of 1.66. The company has a market cap of $24.73 million, a PE ratio of -0.67 and a beta of 2.16.
BIOLASE (NASDAQ:BIOL) last issued its earnings results on Wednesday, November 6th. The medical technology company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.13. The business had revenue of $8.65 million during the quarter. BIOLASE had a negative return on equity of 313.64% and a negative net margin of 52.13%.
A hedge fund recently raised its stake in BIOLASE stock. BlackRock Inc. lifted its position in BIOLASE Inc (NASDAQ:BIOL) by 3.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 298,875 shares of the medical technology company’s stock after acquiring an additional 9,698 shares during the quarter. BlackRock Inc. owned approximately 1.40% of BIOLASE worth $440,000 at the end of the most recent reporting period. 26.88% of the stock is owned by hedge funds and other institutional investors.
BIOLASE Company Profile
BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening.